Logo image of RLYB

RALLYBIO CORP (RLYB) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:RLYB - US75120L1008 - Common Stock

0.732 USD
-0.01 (-1.28%)
Last: 12/12/2025, 4:30:02 PM
0.7201 USD
-0.01 (-1.63%)
After Hours: 12/12/2025, 4:30:02 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RLYB. RLYB was compared to 531 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RLYB as it has an excellent financial health rating, but there are worries on the profitability. RLYB is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RLYB had negative earnings in the past year.
RLYB had a negative operating cash flow in the past year.
In the past 5 years RLYB always reported negative net income.
RLYB had a negative operating cash flow in each of the past 5 years.
RLYB Yearly Net Income VS EBIT VS OCF VS FCFRLYB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -20.88%, RLYB is in the better half of the industry, outperforming 74.76% of the companies in the same industry.
The Return On Equity of RLYB (-22.41%) is better than 81.36% of its industry peers.
Industry RankSector Rank
ROA -20.88%
ROE -22.41%
ROIC N/A
ROA(3y)-62.09%
ROA(5y)-46.14%
ROE(3y)-67.77%
ROE(5y)-49.9%
ROIC(3y)N/A
ROIC(5y)N/A
RLYB Yearly ROA, ROE, ROICRLYB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RLYB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RLYB Yearly Profit, Operating, Gross MarginsRLYB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

RLYB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RLYB has more shares outstanding
Compared to 5 years ago, RLYB has more shares outstanding
There is no outstanding debt for RLYB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RLYB Yearly Shares OutstandingRLYB Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RLYB Yearly Total Debt VS Total AssetsRLYB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

RLYB has an Altman-Z score of -2.82. This is a bad value and indicates that RLYB is not financially healthy and even has some risk of bankruptcy.
RLYB's Altman-Z score of -2.82 is in line compared to the rest of the industry. RLYB outperforms 45.01% of its industry peers.
There is no outstanding debt for RLYB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.82
ROIC/WACCN/A
WACC8.78%
RLYB Yearly LT Debt VS Equity VS FCFRLYB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 14.74 indicates that RLYB has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 14.74, RLYB belongs to the top of the industry, outperforming 90.77% of the companies in the same industry.
A Quick Ratio of 14.74 indicates that RLYB has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 14.74, RLYB belongs to the top of the industry, outperforming 90.77% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 14.74
Quick Ratio 14.74
RLYB Yearly Current Assets VS Current LiabilitesRLYB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

RLYB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 48.75%, which is quite impressive.
RLYB shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.71%.
EPS 1Y (TTM)48.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.15%
Revenue 1Y (TTM)12.71%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-29.1%

3.2 Future

Based on estimates for the next years, RLYB will show a small growth in Earnings Per Share. The EPS will grow by 2.36% on average per year.
Based on estimates for the next years, RLYB will show a very strong growth in Revenue. The Revenue will grow by 165.51% on average per year.
EPS Next Y71.04%
EPS Next 2Y24.25%
EPS Next 3Y18.4%
EPS Next 5Y2.36%
Revenue Next Year8.72%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y165.51%

3.3 Evolution

RLYB Yearly Revenue VS EstimatesRLYB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2029 2030 2031 200M 400M 600M 800M
RLYB Yearly EPS VS EstimatesRLYB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RLYB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RLYB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RLYB Price Earnings VS Forward Price EarningsRLYB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RLYB Per share dataRLYB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

RLYB's earnings are expected to grow with 18.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.25%
EPS Next 3Y18.4%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RLYB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RALLYBIO CORP

NASDAQ:RLYB (12/12/2025, 4:30:02 PM)

After market: 0.7201 -0.01 (-1.63%)

0.732

-0.01 (-1.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)N/A N/A
Inst Owners59.8%
Inst Owner Change-9.21%
Ins Owners2.36%
Ins Owner Change0%
Market Cap30.92M
Revenue(TTM)674.00K
Net Income(TTM)-14.13M
Analysts76
Price Target1.02 (39.34%)
Short Float %0.47%
Short Ratio0.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.96%
Min EPS beat(2)11.96%
Max EPS beat(2)35.96%
EPS beat(4)4
Avg EPS beat(4)20.82%
Min EPS beat(4)11.96%
Max EPS beat(4)35.96%
EPS beat(8)7
Avg EPS beat(8)13.46%
EPS beat(12)11
Avg EPS beat(12)13.67%
EPS beat(16)12
Avg EPS beat(16)9.51%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)20%
EPS NQ rev (3m)28.69%
EPS NY rev (1m)54.9%
EPS NY rev (3m)54.9%
Revenue NQ rev (1m)99.99%
Revenue NQ rev (3m)99.99%
Revenue NY rev (1m)37.5%
Revenue NY rev (3m)35.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 45.87
P/FCF N/A
P/OCF N/A
P/B 0.49
P/tB 0.49
EV/EBITDA N/A
EPS(TTM)-0.82
EYN/A
EPS(NY)-0.62
Fwd EYN/A
FCF(TTM)-0.83
FCFYN/A
OCF(TTM)-0.83
OCFYN/A
SpS0.02
BVpS1.49
TBVpS1.49
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.88%
ROE -22.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.09%
ROA(5y)-46.14%
ROE(3y)-67.77%
ROE(5y)-49.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.74
Quick Ratio 14.74
Altman-Z -2.82
F-Score5
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)12.47%
Cap/Depr(5y)114.15%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.15%
EPS Next Y71.04%
EPS Next 2Y24.25%
EPS Next 3Y18.4%
EPS Next 5Y2.36%
Revenue 1Y (TTM)12.71%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-29.1%
Revenue Next Year8.72%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y165.51%
EBIT growth 1Y45.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-7.15%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45%
OCF growth 3YN/A
OCF growth 5YN/A

RALLYBIO CORP / RLYB FAQ

What is the fundamental rating for RLYB stock?

ChartMill assigns a fundamental rating of 3 / 10 to RLYB.


What is the valuation status of RALLYBIO CORP (RLYB) stock?

ChartMill assigns a valuation rating of 0 / 10 to RALLYBIO CORP (RLYB). This can be considered as Overvalued.


What is the profitability of RLYB stock?

RALLYBIO CORP (RLYB) has a profitability rating of 1 / 10.


How financially healthy is RALLYBIO CORP?

The financial health rating of RALLYBIO CORP (RLYB) is 7 / 10.